Adjuvant effect of B domain of staphyloccocal protein A displayed on the surface of hepatitis B virus capsid

Hyun Jin Kim, Keum Young Ahn, Kyung Dong Bae, Jiyun Lee, Sang Jun Sim, Jeewon Lee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The hepatitis B virus (HBV) capsid-based recombinant particles, which display both major hydrophilic region of HBV surface antigen (HBV-MHR) and B domain of Staphylococcal protein A (SPAB), were produced using Escherichia coli as expression host. SPAB was used as an adjuvant to elicit the immune response to HBV-MHR, and its adjuvant effect in the immunized mice was estimated with varying the position and amount of SPAB on the HBV capsid particles. Compared to the emulsified aluminum gel (alum gel) that is a currently commercialized vaccine adjuvant, SPAB caused the significantly higher level of anti-HBV immunoglobulin G (IgG) titer and seroconversion rate, and notably SPAB at the most surface-exposed position on the recombinant particle led to the highest immune response. Moreover, SPAB caused much lower ratio of IgG1 to IgG2a compared to alum gel, indicating that helper T-cell 1-mediated immune response (responsible for cytotoxic T-cell stimulation) is relatively more stimulated by SPAB, unlike alum gel that mainly stimulates helper T-cell 2-mediated immune response (responsible for B-cell stimulation). Although HBV-MHR and HBV capsid particle were used as proof-of-concept in this study, SPAB can be used as a highly effective adjuvant with other disease-specific antigens on the surface of other virus-like particles to produce various recombinant vaccines with high potency.

Original languageEnglish
Pages (from-to)268-274
Number of pages7
JournalBiotechnology and Bioengineering
Volume113
Issue number2
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Capsid
Staphylococcal Protein A
Viruses
Hepatitis B virus
Proteins
T-cells
Aluminum
Virion
Gels
Antigens
Immunoglobulin G
Th2 Cells
Th1 Cells
Synthetic Vaccines
Vaccines
Surface Antigens
Hepatitis B Surface Antigens
Escherichia coli
Particles (particulate matter)
B-Lymphocytes

Keywords

  • Adjuvant
  • HBV capsid
  • Immunogenicity
  • Protein A
  • Seroconversion

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

Adjuvant effect of B domain of staphyloccocal protein A displayed on the surface of hepatitis B virus capsid. / Kim, Hyun Jin; Ahn, Keum Young; Bae, Kyung Dong; Lee, Jiyun; Sim, Sang Jun; Lee, Jeewon.

In: Biotechnology and Bioengineering, Vol. 113, No. 2, 01.02.2016, p. 268-274.

Research output: Contribution to journalArticle

@article{26a86d6f8c4942a197ddac3b5b2b8aa1,
title = "Adjuvant effect of B domain of staphyloccocal protein A displayed on the surface of hepatitis B virus capsid",
abstract = "The hepatitis B virus (HBV) capsid-based recombinant particles, which display both major hydrophilic region of HBV surface antigen (HBV-MHR) and B domain of Staphylococcal protein A (SPAB), were produced using Escherichia coli as expression host. SPAB was used as an adjuvant to elicit the immune response to HBV-MHR, and its adjuvant effect in the immunized mice was estimated with varying the position and amount of SPAB on the HBV capsid particles. Compared to the emulsified aluminum gel (alum gel) that is a currently commercialized vaccine adjuvant, SPAB caused the significantly higher level of anti-HBV immunoglobulin G (IgG) titer and seroconversion rate, and notably SPAB at the most surface-exposed position on the recombinant particle led to the highest immune response. Moreover, SPAB caused much lower ratio of IgG1 to IgG2a compared to alum gel, indicating that helper T-cell 1-mediated immune response (responsible for cytotoxic T-cell stimulation) is relatively more stimulated by SPAB, unlike alum gel that mainly stimulates helper T-cell 2-mediated immune response (responsible for B-cell stimulation). Although HBV-MHR and HBV capsid particle were used as proof-of-concept in this study, SPAB can be used as a highly effective adjuvant with other disease-specific antigens on the surface of other virus-like particles to produce various recombinant vaccines with high potency.",
keywords = "Adjuvant, HBV capsid, Immunogenicity, Protein A, Seroconversion",
author = "Kim, {Hyun Jin} and Ahn, {Keum Young} and Bae, {Kyung Dong} and Jiyun Lee and Sim, {Sang Jun} and Jeewon Lee",
year = "2016",
month = "2",
day = "1",
doi = "10.1002/bit.25716",
language = "English",
volume = "113",
pages = "268--274",
journal = "Biotechnology and Bioengineering",
issn = "0006-3592",
publisher = "Wiley-VCH Verlag",
number = "2",

}

TY - JOUR

T1 - Adjuvant effect of B domain of staphyloccocal protein A displayed on the surface of hepatitis B virus capsid

AU - Kim, Hyun Jin

AU - Ahn, Keum Young

AU - Bae, Kyung Dong

AU - Lee, Jiyun

AU - Sim, Sang Jun

AU - Lee, Jeewon

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The hepatitis B virus (HBV) capsid-based recombinant particles, which display both major hydrophilic region of HBV surface antigen (HBV-MHR) and B domain of Staphylococcal protein A (SPAB), were produced using Escherichia coli as expression host. SPAB was used as an adjuvant to elicit the immune response to HBV-MHR, and its adjuvant effect in the immunized mice was estimated with varying the position and amount of SPAB on the HBV capsid particles. Compared to the emulsified aluminum gel (alum gel) that is a currently commercialized vaccine adjuvant, SPAB caused the significantly higher level of anti-HBV immunoglobulin G (IgG) titer and seroconversion rate, and notably SPAB at the most surface-exposed position on the recombinant particle led to the highest immune response. Moreover, SPAB caused much lower ratio of IgG1 to IgG2a compared to alum gel, indicating that helper T-cell 1-mediated immune response (responsible for cytotoxic T-cell stimulation) is relatively more stimulated by SPAB, unlike alum gel that mainly stimulates helper T-cell 2-mediated immune response (responsible for B-cell stimulation). Although HBV-MHR and HBV capsid particle were used as proof-of-concept in this study, SPAB can be used as a highly effective adjuvant with other disease-specific antigens on the surface of other virus-like particles to produce various recombinant vaccines with high potency.

AB - The hepatitis B virus (HBV) capsid-based recombinant particles, which display both major hydrophilic region of HBV surface antigen (HBV-MHR) and B domain of Staphylococcal protein A (SPAB), were produced using Escherichia coli as expression host. SPAB was used as an adjuvant to elicit the immune response to HBV-MHR, and its adjuvant effect in the immunized mice was estimated with varying the position and amount of SPAB on the HBV capsid particles. Compared to the emulsified aluminum gel (alum gel) that is a currently commercialized vaccine adjuvant, SPAB caused the significantly higher level of anti-HBV immunoglobulin G (IgG) titer and seroconversion rate, and notably SPAB at the most surface-exposed position on the recombinant particle led to the highest immune response. Moreover, SPAB caused much lower ratio of IgG1 to IgG2a compared to alum gel, indicating that helper T-cell 1-mediated immune response (responsible for cytotoxic T-cell stimulation) is relatively more stimulated by SPAB, unlike alum gel that mainly stimulates helper T-cell 2-mediated immune response (responsible for B-cell stimulation). Although HBV-MHR and HBV capsid particle were used as proof-of-concept in this study, SPAB can be used as a highly effective adjuvant with other disease-specific antigens on the surface of other virus-like particles to produce various recombinant vaccines with high potency.

KW - Adjuvant

KW - HBV capsid

KW - Immunogenicity

KW - Protein A

KW - Seroconversion

UR - http://www.scopus.com/inward/record.url?scp=84965136516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965136516&partnerID=8YFLogxK

U2 - 10.1002/bit.25716

DO - 10.1002/bit.25716

M3 - Article

C2 - 26222886

AN - SCOPUS:84965136516

VL - 113

SP - 268

EP - 274

JO - Biotechnology and Bioengineering

JF - Biotechnology and Bioengineering

SN - 0006-3592

IS - 2

ER -